Gaviscon Advance Chewable Tablets *

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 14 October 2020

File name

Gaviscon Advance Chewable Tablets PIL July 20_1602694967.pdf

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions

Updated on 20 August 2020

File name

Gaviscon Advance Chewable Tablets July20_1597924951.pdf

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.4 - Special warnings and precautions for use

Legal category:Supply through pharmacy only

Updated on 15 January 2020

File name

Gaviscon Advance Tablets_1579097152.pdf

Reasons for updating

  • Change to section 6 - manufacturer

Updated on 21 July 2015

Reasons for updating

  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 4.2 - Posology and method of administration

Legal category:Supply through pharmacy only

Free text change information supplied by the pharmaceutical company

updates to SmPC to align with current company safety information

Updated on 21 July 2015

Reasons for updating

  • New SPC for new product

Legal category:Supply through pharmacy only

Updated on 20 July 2015

File name

PIL_16414_873.pdf

Reasons for updating

  • New PIL for new product

Updated on 14 December 2012

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition

Legal category:Supply through pharmacy only

Free text change information supplied by the pharmaceutical company

Included the following statement in section 2 of SmPC

            Excipient with known effect:  Aspartame (E951) 4.5mg in 1 tablet.

Updated on 15 November 2011

Reasons for updating

  • Change to section 10 - Date of revision of the text
  • Change to section 9 - Date of renewal of authorisation

Legal category:Supply through pharmacy only

Free text change information supplied by the pharmaceutical company

9.         DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
Included the date of last renewal:  05th January 2010

10.       DATE OF REVISION OF THE TEXT
amended to November 2011 

Updated on 15 May 2007

Reasons for updating

  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 6.1 - List of excipients
  • Change to section 6.5 - Nature and contents of container
  • Change to section 7 - Marketing authorisation holder

Legal category:Supply through pharmacy only

Free text change information supplied by the pharmaceutical company

Section 4.1  Therapeutic Indications has been modified slightly.
 
Section 4.3  Contraindication in relation to hypersensitivity to ingredients has been reworded
 
Section 4.6  Pregnancy and Lactation.  An additional statement that duration of treatment should be limited as much as possible due to the presence of calcium carbonate.
 
Section 6.1  Excipients have been updated. 
 
Section 6.5.  Additional pack size of 60 tablets.  Expansion of description of 20 and 60 container.
 
Section 7.  Change of address of marketing authorisation holder to: 7 Riverwalk, Citywest Business Campus, Dublin 24, Ireland

Updated on 04 August 2006

Reasons for updating

  • New SPC for new product

Legal category:Supply through pharmacy only